Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADZENYS ER vs ADDERALL 20
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy,Off-label: Treatment-resistant depression, obesity, cognitive enhancement
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
Metabolized primarily by hepatic esterases and cytochrome P450 (CYP) enzymes, including CYP2D6.
Primarily hepatic via CYP2D6 and, to a lesser extent, CYP2C19, CYP3A4, and CYP2C9. Metabolites include 4-hydroxyamphetamine, alpha-hydroxyamphetamine, and norephedrine.
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
97% bound to albumin and α1-acid glycoprotein
16% (primarily albumin).
4.6-6.8 L/kg, indicating extensive tissue distribution, particularly in brain and adipose tissue
3.2-5.6 L/kg; indicates extensive tissue distribution.
Oral: 95% ± 10%; rectal: 80% ± 15%
Oral IR: ~90%; ER: ~90%.
GFR 30-89 m L/min: No adjustment. GFR <30 m L/min: Not recommended.
e GFR 15-29 m L/min: 50% of usual dose. e GFR < 15 m L/min: avoid use due to accumulation risk. Hemodialysis: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Not recommended.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use.
Children ≥6 years: Initial 5-10 mg orally once daily; titrate weekly by 5-10 mg; max 1 mg/kg/day or 60 mg/day, whichever is lower.
Children 3-5 years: 2.5 mg orally once daily; increase by 2.5 mg weekly. Children 6 years and older: 5 mg once or twice daily; increase by 5 mg weekly. Maximum dose: 40 mg/day (immediate-release). Weight-based: 0.3-1.5 mg/kg/day (immediate-release).
Initiate at 5 mg once daily; titrate cautiously; monitor for cardiovascular effects and insomnia.
Initial: 2.5 mg once or twice daily; increase slowly by 2.5 mg increments at weekly intervals. Use lowest effective dose due to increased sensitivity and risk of cardiovascular adverse effects.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including ADZENYS ER, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Abuse and dependence: Amphetamines have a high potential for abuse, which can lead to dependence and serious cardiovascular events. Misuse may cause sudden death or serious cardiovascular adverse events.
Serious cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported in patients with pre-existing cardiac abnormalities.,Blood pressure and heart rate increase: Monitor regularly.,Psychiatric adverse reactions: May precipitate or exacerbate psychosis or mania.,Long-term suppression of growth in pediatric patients: Monitor height and weight.,Seizures: May lower seizure threshold in patients with history of seizures.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Cardiovascular: Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities.,Psychiatric: Exacerbation of pre-existing psychosis, mania, or aggression; new-onset psychosis or mania.,Growth suppression: Long-term use in children may suppress growth.,Seizures: May lower seizure threshold in patients with seizure disorders.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Known hypersensitivity to amphetamines or other components of ADZENYS ER,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Agitated states,History of drug abuse,Cardiovascular disease including hypertension, arteriosclerosis, hyperthyroidism, glaucoma
Hypersensitivity to amphetamine or any component of the formulation,Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use or within 14 days of MAO inhibitors (risk of hypertensive crisis)
High-fat meals can significantly delay and reduce the absorption of Adzenys ER; the time to peak concentration (Tmax) may be prolonged by approximately 1 hour and peak concentration (Cmax) reduced by about 38%. It is recommended to take Adzenys ER on an empty stomach (at least 1 hour before or 2 hours after a meal) to ensure consistent effect. Avoid alcohol while taking this medication, as it may increase the risk of cardiovascular side effects and impair judgment. No other specific food interactions are known, but patients should maintain a balanced diet to manage potential appetite suppression common with amphetamines.
High-fat meals can delay absorption of Adderall. Acidic foods (e.g., citrus fruits, juices) and vitamin C may decrease absorption; avoid within 1 hour of dosing. Caffeine and other stimulants may increase side effects. Alcohol should be avoided. Grapefruit juice may increase amphetamine levels, so limit or avoid.
First trimester: Inadequate human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to neonatal withdrawal syndrome (hyperactivity, irritability, poor feeding) and reduced fetal growth. Avoid in first trimester unless benefit outweighs risk; use lowest effective dose in later trimesters.
First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of fetal growth restriction, preterm birth, neonatal withdrawal syndrome (irritability, poor feeding), and persistent pulmonary hypertension. Chronic use may impair fetal development.
Excreted in breast milk; M/P ratio approximately 2.6. Irritability and weight loss reported in nursing infants. Not recommended unless benefit outweighs risk.
Excreted into breast milk; M/P ratio approximately 2.5–7.5. Relative infant dose estimated at 5–14% of maternal weight-adjusted dose. Potential for decreased appetite, insomnia, and growth suppression in breastfed infants. American Academy of Pediatrics recommends use only if benefit outweighs risk, with close monitoring.
Clearance increased by approximately 30% in third trimester; may require dose escalation. Postpartum dose reduction may be needed to avoid toxicity. Individual titration based on clinical response and tolerability.
Due to increased renal clearance and expanded plasma volume, total amphetamine exposure may decrease, potentially requiring dose increase (monitor clinical response). However, insufficient data to recommend fixed adjustments; individualize based on symptom control and tolerability.
Adzenys ER is an extended-release oral suspension of amphetamine (mixed salts) for ADHD. It provides a rapid onset (within 1 hour) and sustained effect over 10-12 hours. The suspension must be shaken vigorously for at least 10 seconds before each use. Dose titration should be guided by efficacy and tolerability, starting at 6.3 mg once daily in the morning for children 6-12 years. Avoid administration with high-fat meals as they may delay absorption (Cmax reduced by ~38%). Monitor for cardiovascular effects: heart rate, blood pressure, and potential for sudden death in patients with structural cardiac abnormalities. Use cautiously in patients with pyschosis, bipolar disorder, hypertension, hyperthyroidism, glaucoma, or history of drug abuse. Discontinue if agitation, aggression, or manic symptoms emerge. Drug holidays (weekend or holiday breaks) may be considered to assess need and reduce tolerance.
Adderall 20 mg is a mixed amphetamine salt formulation (75% dextroamphetamine, 25% levoamphetamine). Monitor for cardiovascular adverse effects; consider baseline ECG in patients with cardiac risk factors. Avoid in patients with structural cardiac abnormalities, cardiomyopathy, or arrhythmias. Use with caution in patients with hypertension, hyperthyroidism, or glaucoma. May exacerbate tics and Tourette syndrome. Administer first dose upon awakening; avoid afternoon doses due to insomnia risk. Monitor growth in children; may cause weight loss and growth suppression. Assess for potential for abuse and dependence; use lowest effective dose.
Take Adzenys ER exactly as prescribed, once daily in the morning; do not take in the afternoon or evening to avoid insomnia.,Shake the bottle vigorously for at least 10 seconds before each use; use the provided oral syringe to measure the correct dose.,Do not mix the medication with food or liquids; take it directly from the syringe.,Avoid taking with high-fat meals, as they may delay and reduce the drug's effect; take on an empty stomach if possible.,Store at room temperature (20-25°C); protect from light and moisture. Discard any unused portion after 30 days of opening.,Notify your doctor immediately if you experience chest pain, shortness of breath, fainting, or palpitations.,This medication has a high potential for abuse; do not share it with others and keep in a safe place.,Inform your doctor about all other medications, including OTC drugs and supplements, especially MAOIs (avoid within 14 days), antihypertensives, and SSRIs.
Take exactly as prescribed; do not crush or chew extended-release capsules.,Take early in the morning to avoid trouble sleeping.,Avoid taking with high-fat meals as it may delay absorption.,Do not drink alcohol while taking this medication.,Report any chest pain, shortness of breath, or fainting immediately.,Avoid driving or operating heavy machinery until you know how Adderall affects you.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.,Do not share your medication with others; it is a controlled substance.,Inform your doctor if you have a history of heart disease, high blood pressure, seizures, or mental health conditions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADZENYS ER vs ADDERALL 20, answered by our medical review team.
ADZENYS ER is a CNS Stimulant that works by ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.. ADDERALL 20 is a CNS Stimulant that works by Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADZENYS ER and ADDERALL 20 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADZENYS ER is: Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.. The standard adult dose of ADDERALL 20 is: Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADZENYS ER and ADDERALL 20 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADZENYS ER is classified as Category C. First trimester: Inadequate human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to neonata. ADDERALL 20 is classified as Category C. First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.